Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026)

InMed Pharmaceuticals has reported Income from Continuing Operations over the past 5 years, most recently at 2028223.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 21.23% year-over-year to 2028223.0; the TTM value through Dec 2025 reached 7664363.0, up 3.06%, while the annual FY2025 figure was 8162133.0, 6.34% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 2028223.0 at InMed Pharmaceuticals, down from 1726899.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 336591.0 in Q2 2023 and troughed at 7870023.0 in Q2 2022.
  • A 5-year average of 2562619.11 and a median of 2063155.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 95.72% in 2023 and later crashed 473.57% in 2024.
  • Year by year, Income from Continuing Operations stood at 4282814.0 in 2021, then skyrocketed by 51.01% to 2098087.0 in 2022, then increased by 29.55% to 1478185.0 in 2023, then crashed by 74.2% to 2575024.0 in 2024, then increased by 21.23% to 2028223.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for INM at 2028223.0 in Q4 2025, 1726899.0 in Q3 2025, and 1788311.0 in Q2 2025.